The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI

European Journal of Surgical Oncology

Volumn 35, Issue 8, 2009, Pages 870-876

  Kim, H S ^a   Kim, J W ^a   Cho, J Y ^a   Chung, H H ^a   Park, N H ^a   Song, Y S ^a   Kim, S H ^a   Kang, S B ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Advanced stage disease; CT; Early stage epithelial ovarian cancer; MRI; Serum CA 125 level

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; ASCITES; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY; OVARY CANCER; OVARY CLEAR CELL CARCINOMA; OVARY MUCINOUS CARCINOMA; OVARY SEROUS CARCINOMA; PELVIS; PERITONEUM; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67549135943     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2009.01.005     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Kim H.S., Kim T.H., Chung H.H., et al. Clinical analysis for the prognostic factors in patients with recurrent epithelial ovarian cancer who underwent secondary cytoreductive surgery. J Gynecol Oncol 19 (2008) 75-80
3. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95 Suppl. 1 (2006) S161-S192
4. Onda T., Yoshikawa H., Yasugi T., et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer 83 (1998) 1555-1560
5. Onda T., Yoshikawa H., Yokota H., et al. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer 78 (1996) 803-808
6. Di Re F., Baiocchi G., Fontanelli R., et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol 62 (1996) 360-365
7. Castellucci P., Perrone A.M., Picchio M., et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 28 (2007) 589-595
8. Triller J., Goldhirsch A., and Fuchs W.A. Value of computed tomography for the assessment of lymph node metastases in ovarian cancer. Rofo 141 (1984) 35-39
9. Kim H.S., Park N.H., Chung H.H., et al. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie 31 (2008) 315-320
10. Santillan A., Garg R., Zahurak M.L., et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 23 (2005) 9338-9343
11. Crawford S.C., Vasey P.A., Paul J., et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 23 (2005) 8802-8811
12. Wakabayashi M.T., Lin P.S., and Hakim A.A. The role of cytoreductive/debulking surgery in ovarian cancer. J Natl Compr Canc Netw 6 (2008) 803-810
13. Panici P.B., Maggioni A., Hacker N., et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97 (2005) 560-566
14. Chan J.K., Urban R., Hu J.M., et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients. Br J Cancer 96 (2007) 1817-1822
15. Cho Y.H., Kim D.Y., Kim J.H., et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?. Gynecol Oncol 103 (2006) 878-882
16. Wang Z., Xiong Z., and Wang S. Effect of retroperitoneal lymphadenectomy on prognosis of patients with epithelial ovarian cancer. Chin Med J (Engl) 116 (2003) 588-592
17. Camatte S., Morice P., Atallah D., et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg 195 (2002) 332-338
18. Kim H.S., Park N.H., Chung H.H., et al. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer. Acta Obstet Gynecol Scand 87 (2008) 1136-1142
19. Tsumura N., Sakuragi N., Hareyama H., et al. Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer 79 (1998) 526-530
20. Buy J.N., Moss A.A., Ghossain M.A., et al. Peritoneal implants from ovarian tumors: CT findings. Radiology 169 (1988) 691-694
21. Yoshimura S., Scully R.E., Bell D.A., et al. Correlation of ascitic fluid cytology with histologic findings before and after treatment of ovarian cancer. Am J Obstet Gynecol 148 (1984) 716-721
22. La Fianza A., Campani R., Dore R., et al. The clinical value of computed tomography and lymphography in detecting lymph node metastases from epithelial ovarian cancer. Rofo 157 (1992) 162-166
23. Lorenzen M., Braun J., Gehrckens A., et al. Value of MRI, CT and findings in staging of gynecologic malignancies. Aktuelle Radiol 8 (1998) 266-272
24. Ricke J., Sehouli J., Hach C., et al. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 13 (2003) 943-949
25. Drieskens O., Stroobants S., Gysen M., et al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 55 (2003) 130-134
26. Liu P.Y., Albert D.S., Monk B.J., et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 25 (2007) 3615-3620